Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

A Controversial Question in Uterine Cancer Treatment Has Been Answered

A Controversial Question in Uterine Cancer Treatment Has Been Answered

The womb, medically called the uterus, is a female reproductive organ where the fetus grows during pregnancy. It has two layers: the inner layer is the endometrium , while the outer muscular layer is the myometrium. Cancerous changes in endometrial cells produce endometrial cancer , the most common female reproductive organ cancer.

You May Be Interested In:

The endometrial cancer treatment plan depends on expected disease course, extent (stage) and microscopic appearance of cancer cells. Surgery is important for staging and treatment. After surgery, treatment planning requires identifying the disease risk group . There are three groups: low, intermediate and high risk.

Low-Risk Group: Cancer confined to the uterine endometrium (Stage IA), without serous or clear-cell appearance, is considered low risk. Surgery alone is sufficient because recurrence risk is below %5.

Intermediate-Risk Group: Cancer spreading into the muscular myometrium or microscopically reaching the cervix, without serous or clear-cell appearance, is considered intermediate risk. Radiotherapy is recommended as preventive-adjuvant treatment.

High-Risk Group: Serous or clear-cell cancer, cancer reaching the cervix or vagina (birth canal), or extending beyond the uterus is high-risk disease. There is no single preventive treatment approach. Two important studies determining adjuvant treatment for these patients were presented at the American Cancer Congress ASCO 2017.

What Should Postoperative Preventive Treatment Be in Uterine Cancer?

After surgery with no visible cancer remaining, 660 high-risk endometrial cancer patients entered the PORTEC-3 trial. It asked whether both chemotherapy and radiotherapy were needed to prevent recurrence. Of these, 330 received radiotherapy alone and 330 received radiotherapy with chemotherapy. Patients were followed for an average of 60 months. Five-year survival and time to recurrence did not differ between groups, meaning adding chemotherapy to radiotherapy provided no additional benefit.

When a subgroup analysis was performed by disease stage, combined chemotherapy and radiotherapy benefited stage III patients most (an additional %11 benefit). In high-risk early-stage patients, adding chemotherapy to radiotherapy provided no benefit.

The second study asked whether adding radiotherapy to chemotherapy benefited locally advanced endometrial cancer—without distant metastases but not very early-stage. In this trial, GOG 258, patients receiving only chemotherapy were compared with patients receiving concurrent chemotherapy and radiotherapy followed by chemotherapy; survival and time to recurrence did not differ. Radiotherapy with chemotherapy was associated with more frequent recurrence through distant-organ spread. We considered that this might relate to insufficient chemotherapy delivery in patients receiving radiation.

Conclusion

Both studies provided important information. For postoperative endometrial cancer prevention, highly toxic chemotherapy with concurrent radiotherapy appeared inappropriate both in early disease and in locally advanced disease with greater abdominal growth and spread.

According to these two studies, if cancer is confined to the uterus without spreading beyond it or to adjacent organs, radiotherapy alone can be used considering tumor characteristics. If it has spread within the abdomen, postoperative chemotherapy may be more effective, while adding radiotherapy provides no benefit in this group.

We believe these two studies, important to daily practice, will positively influence future recommendations, enabling greater benefit with less treatment and fewer unnecessary adverse effects.

Sources

1. Final results of the international randomized PORTEC-3 trial of adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer.
2017 ASCO Annual Meeting. Abstract No: 5502

2. A randomized phase III trial of cisplatin and tumor volume directed irradiation followed by carboplatin and paclitaxel vs. carboplatin and paclitaxel for optimally debulked, advanced endometrial carcinoma.
2017 ASCO Annual Meeting. Abstract No: 5505

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

A Controversial Question in Uterine Cancer Treatment Has Been Answered

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy